조현병 환자에서 항정신약물이 대사지표에 미치는 영향 조사 - 1년 추적연구
A Study on Changes of Metabolic Parameters with Antipsychotic Treatment in Schizophrenic Patients : 1 Year Prospective Natualistic Study
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Objectives : Schizophrenia patients are known to be more prone to metabolic disease than normal people. This study aimed to identifythe changes in metabolic parameters of schizophrenia patients using atypical antipsychotic drugs for 1 year. Methods : A total of 200 schizophrenia patients were recruited and categorized into the aripiprazole-treatment group and controlgroup taking 5 atypical antipsychotic drugs. Comparative analysis were between groups. The prescriptions of psychotropic drugswere collected by a review of medical records. Blood was collected after fasting for 12 hours at the starting point of treatment andthe 12th month, and patient medical records were evaluated for basici nformation and treatment history. Physical measurement,the prevalence of metabolic syndrome and metabolic parameters were studied using ATP-III diagnostic criteria. Results : From the study, the aripiprazole-treatment group had a mean weight increase of 0.6 kg and the control group had amean weight increase of 6.5 kg at the 1 year follow-up, showing a significant difference between the two groups. There were alsosignificant differences between the two groups in waist size, systolic and diastolic blood pressure, fasting blood sugar, total cholesterol,triglyceride, HDL-choleseterol and prolactin level. Along with meaningful improvement of the symptoms, aripiprazoletreatmentgroup showed less effect on in abdominal obesity, diabetes, blood pressure, cholesterol and prolactin than other atypicalantipsychotic drugs. Conclusion : Therapeutic intervention such as diagnosis, treatment, weight management and diet improvement is necessary forschizophrenia patients. Psychiatric symptoms as well as internal meicine-related problems such as metabolic disease need to beaddressed in case management.
Abstract
Objectives : Schizophrenia patients are known to be more prone to metabolic disease than normal people. This study aimed to identifythe changes in metabolic parameters of schizophrenia patients using atypical antipsychotic drugs for 1 year. Methods : A total of 200 schizophrenia patients were recruited and categorized into the aripiprazole-treatment group and controlgroup taking 5 atypical antipsychotic drugs. Comparative analysis were between groups. The prescriptions of psychotropic drugswere collected by a review of medical records. Blood was collected after fasting for 12 hours at the starting point of treatment andthe 12th month, and patient medical records were evaluated for basici nformation and treatment history. Physical measurement,the prevalence of metabolic syndrome and metabolic parameters were studied using ATP-III diagnostic criteria. Results : From the study, the aripiprazole-treatment group had a mean weight increase of 0.6 kg and the control group had amean weight increase of 6.5 kg at the 1 year follow-up, showing a significant difference between the two groups. There were alsosignificant differences between the two groups in waist size, systolic and diastolic blood pressure, fasting blood sugar, total cholesterol,triglyceride, HDL-choleseterol and prolactin level. Along with meaningful improvement of the symptoms, aripiprazoletreatmentgroup showed less effect on in abdominal obesity, diabetes, blood pressure, cholesterol and prolactin than other atypicalantipsychotic drugs. Conclusion : Therapeutic intervention such as diagnosis, treatment, weight management and diet improvement is necessary forschizophrenia patients. Psychiatric symptoms as well as internal meicine-related problems such as metabolic disease need to beaddressed in case management.
참고문헌 (26)
- Marder SR, "Physical health monitoring of patients with schizophrenia", Am J Psychiatry, 161, pp.1334~1349 (2004)
- Haupt DW, "Different metabolic effects of antipsychotic treatments", Eur Neuropsychopharmacol, 16, pp.149~155 (2006)
- Newcomer JW, "Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia", Arch Gen Psychiatry, 59, pp.337~345 (2002)
- Faulkner G, "Body mass index, waist circumference and quality of life in individuals with schizophrenia", Schizophr Res, 90, pp.174~178 (2007)
- Czobor P, "Antipsychotic-induced weight gain and therapeutic response: a differential association", J Clin Psychopharmacol, 22, pp.244~251 (2002)
- Lambert M, "Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence", Eur Psychiatry, 19, pp.415~422 (2004)
- Baptista T, "Body weight gain induced by antipsychotic drugs; mechanisms and management", Acta Psychiatr Scand, 100, pp.3~16 (1999)
- Byerly M, "Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives", J Clin Psychopharmacol, 27, pp.639~661 (2007)
- Meyer JM, "The effects of antipsychotic therapy on serum lipids : a comprehensive review", Schizophr Res, 70, pp.1~17 (2004)
- McEvoy JP, "Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trialsof Intervention Effectiveness(CATIE) schizophrenia trial and comparison with national estimates from NHANES III", Schizophr Res, 80, pp.19~32 (2005)
- Casey DE, "Metabolic issues and cardiovascular disease in patients with psychiatric disorders", Am J Med, 118, pp.15~22 (2005)
- L'Italien GJ, "Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo", J Clin Psychiatry, 68, pp.1510~1516 (2007)
- Lambert M, "Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence", Eur Psychiatry, 19, pp.415~422 (2004)
- American Psychiatric Association, "The diagnostic and statistical manual of mental disorder" (1994), American Psychiatric Press
- Ma GF, "Agonist and antagonist effects of aripiprazole on D2-like receptors controlling rat brain dopamine synthesis depend on the dopaminergic tone", Int J Neuropsychopharmacol, 18, pp.1~9 (2014)
- FLB457, "Psychopharmacology (Berl)", 012, 165~172
- "Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adult (Adult Treatment Panel III)", JAMA, 285, pp.2486~2497 (2001)
- "The asia-pacific perspective: redefining obesity and its treatment" (2000), Health Communications Australia Pty Limit
- Meyer JM, "The effects of antipsychotic therapy on serum lipids: a comprehensive review", Schizophr Res, 70, pp.1~17 (2004)
- McQuade RD, "A comprehensive of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study", J Clin Psychiatry, 65(suppl 18), pp.47~56 (2004)
- Fleischhacker WW, "A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia", Biol Psychiatry, 65, pp.510~517 (2009)
- Allison DB, "Antipsychotic-induced weight gain: a review of the literature", J Clin Psychiatry, 62, pp.22~31 (2001)
- Saravane D, "Avec le soutien institutionnel du laboratoire Lilly. Drawing up guidelines for the attendance of physical health of patients with severe mental illness", Encephale, 35, pp.330~339 (2009)
- 고유경, "The Prevalence of Metabolic Syndrome in Schizophrenic Patients Using Antipsychotics", Clinical Psychopharmacology and Neuroscience, 11(2), pp.80~88 (2013), 대한정신약물학회
- Compton MT, "Antipsychotic-induced hyperprolactinemia and sexual dysfunction", Psychopharmacol Bull, 36, pp.143~164 (2002)
- Hanssens L, "The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients:results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913)", BMC Psychiatry, 8, pp.95~ (2008)